Enanta Pharmaceuticals (ENTA) Operating Expenses (2012 - 2026)

Enanta Pharmaceuticals has reported Operating Expenses for 15 years, with the latest figure at $29.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 26.47% year-over-year to $29.0 million; the trailing twelve-month figure through Mar 2026 stood at $129.6 million (down 22.2% YoY), and the FY2025 full-year result was $150.7 million, down 20.42% from the prior year.
• Operating Expenses for Q1 2026 stood at $29.0 million, down from $29.9 million in the prior quarter.
• The five-year high for Operating Expenses was $57.2 million in Q1 2023, with the low at $29.0 million in Q1 2026.
• Historically, Operating Expenses has averaged $45.1 million across 5 years, with a median of $47.4 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Expenses advanced 8.91% — and 2026, when it declined 26.47%.
• Enanta Pharmaceuticals' Operating Expenses stood at $53.6 million in 2022, then fell by 1.32% to $52.9 million in 2023, then retreated by 23.42% to $40.5 million in 2024, then dropped by 26.26% to $29.9 million in 2025, then declined by 2.87% to $29.0 million in 2026.
• The last three Operating Expenses figures came in at $29.0 million (Q1 2026), $29.9 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.